

9A
man



STATE OF NEW HAMPSHIRE
DEPARTMENT OF HEALTH AND HUMAN SERVICES

DIVISION OF PUBLIC HEALTH SERVICES

29 HAZEN DRIVE, CONCORD, NH 03301

603-271-4501 1-800-852-3345 Ext. 4501

Fax: 603-271-4827 TDD Access: 1-800-735-2964

www.dhhs.nh.gov

Lori A. Shibinette
Commissioner

Tricia M. Tilley
Director

August 24, 2021

The Honorable Ken Weyler, Chairman
Fiscal Committee of the General Court
State House
Concord, NH 03301

His Excellency, Governor Christopher T. Sununu
and the Honorable Council
State House
Concord, NH 03301

REQUESTED ACTION

Pursuant to the provisions of RSA 14:30-a, VI, authorize the Department of Health and Human Services, Division of Public Health Services, to accept and expend federal funds in the amount of \$754,823 from the Centers for Disease Control and Prevention (CDC) to fund Advanced Molecular Detection (AMD) Sequencing and Analytics and Strengthening PHL Preparedness as mandated by the American Rescue Plan, effective upon approval by the Fiscal Committee and Governor and Council through June 30, 2023 and further authorize the funds to be allocated as follows. 100% Federal Funds.

05-095-090-903010-24550000 HEALTH AND SOCIAL SERVICES, DEPT OF HEALTH AND HUMAN SERVICES, HHS: DIVISION OF PUBLIC HEALTH SERVICES, PUBLIC HEALTH LABORATORIES, ELC-ARP-AMD & PHL PREP

Class/Obj	Class Title	Current Modified Budget	Increase (Decrease) Amount	Revised Modified Budget
000-400146	Federal Funds	\$0	\$754,823	\$754,823
	General Funds			
	Total Revenue	\$0	\$754,823	\$754,823
020-500200	Current Expense	\$0	\$100,000	\$100,000
030-500302	Equipment	\$0	\$289,836	\$289,836
037-500173	Technology - Hardware	\$0	\$3,000	\$3,000
038-500175	Technology - Software	\$0	\$8,000	\$8,000
041-500801	Audit Fund Set Aside	\$0	\$1,789	\$1,789

102-500731	Contracts for Program Services	\$0	\$76,000	\$76,000
548-500396	Reagents	\$0	\$276,198	\$276,198
	Total Expenses	\$0	\$754,823	\$754,823

EXPLANATION

This request is being made to accept additional grant funds available for the Advanced Molecular Detection (AMD) Sequencing and Analytics and Strengthening PHL Preparedness from the Centers of Disease Control and Prevention (CDC). The rapid emergence and global spread of SARS-CoV-2, the pathogen that causes COVID-19, highlights the threat posed by novel pathogens. One of the most versatile tools in understanding and guiding the response to these emergencies is genomic sequencing. While the ability to decode microbial genomes has existed since the 1970s, the advent of high-throughput DNA sequencing, also called next-generation sequencing, has greatly expanded the use of these technologies in public health.

The COVID -19 pandemic has highlighted many challenges within the laboratory testing infrastructure during an immense public health response. This funding opportunity includes strategies to strengthen surveillance, detection, and preparedness through the Laboratory Response Network (LRN) and at CDC. With more than 120 national, state and local laboratories, the LRN is an integral part of the National Response Framework and ensures consistent, high confidence results by developing and distributing assays, offering specialized training, and supporting data reporting.

The funds are to be budgeted as follows:

Class 020 - The funds will be used to pay for current expenses such as laboratories consumable supplies.

Class 037 - The funds will be used to pay for two laptop computers and accessories. The PHL performs whole genome sequencing for SARS-CoV-2 and foodborne disease pathogens and generates 40-50Gb sequencing data. The PHL purchased a BaseSpace Cloud account from Illumina INC to manage the sequence data. All PHL whole genome sequencing data are transferred to and stored in the BaseSpace Cloud account. The PHL also uses software programs in the BaseSpace Cloud to analyze the PHL sequencing data. Funds are requested to purchase two computers to access to the BaseSpace Cloud account. These two computers will be placed in the PHL's Molecular Diagnostics Laboratory and will be dedicated computers for performing sequencing analysis.

Class 038 - The funds will be used for LIMS integration. The PHL performs whole genome sequencing for SARS-CoV-2 and foodborne disease pathogens and generates large amounts of sequencing data. Currently, sequencing data is stored separately from the associated patient and epidemiologic data. Sharing of this data with NH Epidemiologists required a time-intensive manual combining of the two data sets. In order to use sequencing data efficiently, the PHL will work to integrate sequencing data with patient information and epidemiologic data for the automated sharing of analyzed Next Generation Sequencing (NGS) data with NH Epidemiologists. The PHL currently shares testing data (not including sequencing data) with the NH Bureau of Disease Control (BIDC) through its Horizon Laboratory Information Management System (LIMS). The NPHL will also explore the feasibility of integrating LIMS with data sharing tools and may develop other mechanisms for sharing sequencing data and epidemiology data between the PHL and the BIDC.

Class 041 - The funds will be used to pay for audit fund set aside per State requirement.

Class 102 - The funds will be used pay for contracts including a service contract on the Miseq System, Whole Genome Sequencing (WGS) data storage and computation and a courier contract to deliver specimens. The PHL purchased two MiSeq systems from Illumina INC for performing whole genome sequencing. This MiSeq system is the only system for which the CDC has a standard protocol available for state PHLs to use. Funds are requested to purchase a service and repair contract for the two MiSeq system. The PHL also purchased a BaseSpace Cloud

The Honorable Ken Weyler, Chairman
His Excellency, Governor Christopher T. Sununu
Page 3 of 3

account from Illumina INC to manage the sequence data. Funds are requested to pay the cost of the BaseSpace Cloud account.

Class 548 - The funds will be used to pay for reagents, used in laboratory testing.

In response to the anticipated two-part question, "Can these funds be used to offset General Funds?" and "What is the compelling reason for not offsetting General Funds?" the Division offers the following information: The funds are provided for a specified purpose by the CDC as defined in the Notice of Grant Award and cannot be used to offset general funds.


Area Served: Statewide

Source of Funds: 100% Federal from the Centers for Disease Control and Prevention provided through one-time funding made available under the American Rescue Plan Act (ARP), P.L. 117-2.

Attached is the Notice of Grant Award. These funds were not added to the FY22-FY23 operating budget because these are new funds recently granted to the State to assist in the public health Coronavirus response and were not anticipated at the time the budget was developed.

In the event that these Federal Funds become no longer available, General Funds will not be requested to support this program.

Respectfully submitted,



Lori A. Shibinette
Commissioner

Fiscal Situation

ARP ELC AMD Sequencing, Analysis & Strengthening PHL Preparedness

New Award

NU50CK000522-02-08

Award Ending 07/31/2024

1,789,471

Allocated Costs budgeted throughout the Dept

(1,034,648)

Expended through 6/30/21

-

Unobligated Balance Unable to Spend

-

Award Balance SFY 22

\$ 754,823

Available to Accept in SFY 22

754,823

Amount Requested this Action

754,823



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award

Award# 6 NU50CK000522-02-08

FAIN# NU50CK000522

Federal Award Date: 05/12/2021

Recipient Information

1. Recipient Name

New Hampshire DHHS
129 Pleasant St
Concord, NH 03301-3852
[NO DATA]

2. Congressional District of Recipient

02

3. Payment System Identifier (ID)

1026000618B3

4. Employer Identification Number (EIN)

026000618

5. Data Universal Numbering System (DUNS)

011040545

6. Recipient's Unique Entity Identifier

7. Project Director or Principal Investigator

CHRISTINE LOUISE BEAN
christine.bean@dhhs.nh.gov
6032714657

8. Authorized Official

Ms. Richelle Swanson
AO / Finance Director
Richelle.Swanson@dhhs.nh.gov
603-271-4613

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Cathleen Franklin
Grants Management Specialist
qtm0@cdc.gov
678-475-4552

10. Program Official Contact Information

Mr. Fred Maxineau
PHA
hyx2@cdc.gov
404.639.0869

Federal Award Information

11. Award Number

6 NU50CK000522-02-08

12. Unique Federal Award Identification Number (FAIN)

NU50CK000522

13. Statutory Authority

301(A)AND317(K)(2)PHS42USC241(A)247B(K)2

14. Federal Award Project Title

Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC)

15. Assistance Listing Number

93.323

16. Assistance Listing Program Title

Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)

17. Award Action Type

Supplement

18. Is the Award R&D?

No

Summary Federal Award Financial Information

Table with 2 columns: Description and Amount. Rows include Budget Period Start Date (08/01/2020 - End Date 07/31/2021), Total Amount of Federal Funds Obligated by this Action (\$1,789,471.00), Authorized Carryover (\$0.00), Offset (\$0.00), Total Amount of Federal Funds Obligated this budget period (\$122,850,353.00), Total Approved Cost Sharing or Matching, where applicable (\$0.00), Total Federal and Non-Federal Approved this Budget Period (\$124,639,824.00), Project Period Start Date (08/01/2019 - End Date 07/31/2024), Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period (Not Available).

28. Authorized Treatment of Program Income

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Ms. Freda Johnson
Grants Management Officer

30. Remarks



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award

Award# 6 NU50CK000522-02-08

FAIN# NU50CK000522

Federal Award Date: 05/12/2021

<p>Recipient Information</p> <p>Recipient Name New Hampshire DHHS 129 Pleasant St Concord, NH 03301-3852 [NO DATA]</p> <p>Congressional District of Recipient 02</p> <p>Payment Account Number and Type 1026000618B3</p> <p>Employer Identification Number (EIN) Data 026000618</p> <p>Universal Numbering System (DUNS) 011040545</p> <p>Recipient's Unique Entity Identifier Not Available</p>	<p>33. Approved Budget (Excludes Direct Assistance)</p> <p>I. Financial Assistance from the Federal Awarding Agency Only</p> <p>II. Total project costs including grant funds and all other financial participation</p> <table border="1" style="width: 100%;"> <tr> <td>a. Salaries and Wages</td> <td style="text-align: right;">\$4,581,292.00</td> </tr> <tr> <td>b. Fringe Benefits</td> <td style="text-align: right;">\$2,189,594.00</td> </tr> <tr> <td> c. Total Personnel Costs</td> <td style="text-align: right;">\$6,770,886.00</td> </tr> <tr> <td>d. Equipment</td> <td style="text-align: right;">\$994,353.00</td> </tr> <tr> <td>e. Supplies</td> <td style="text-align: right;">\$15,266,233.00</td> </tr> <tr> <td>f. Travel</td> <td style="text-align: right;">\$70,369.00</td> </tr> <tr> <td>g. Construction</td> <td style="text-align: right;">\$0.00</td> </tr> <tr> <td>h. Other</td> <td style="text-align: right;">\$44,266,593.00</td> </tr> <tr> <td>i. Contractual</td> <td style="text-align: right;">\$49,646,230.00</td> </tr> <tr> <td>j. TOTAL DIRECT COSTS</td> <td style="text-align: right;">\$117,014,664.00</td> </tr> <tr> <td>k. INDIRECT COSTS</td> <td style="text-align: right;">\$7,625,160.00</td> </tr> <tr> <td>l. TOTAL APPROVED BUDGET</td> <td style="text-align: right;">\$124,639,824.00</td> </tr> <tr> <td>m. Federal Share</td> <td style="text-align: right;">\$124,639,824.00</td> </tr> <tr> <td>n. Non-Federal Share</td> <td style="text-align: right;">\$0.00</td> </tr> </table>	a. Salaries and Wages	\$4,581,292.00	b. Fringe Benefits	\$2,189,594.00	c. Total Personnel Costs	\$6,770,886.00	d. Equipment	\$994,353.00	e. Supplies	\$15,266,233.00	f. Travel	\$70,369.00	g. Construction	\$0.00	h. Other	\$44,266,593.00	i. Contractual	\$49,646,230.00	j. TOTAL DIRECT COSTS	\$117,014,664.00	k. INDIRECT COSTS	\$7,625,160.00	l. TOTAL APPROVED BUDGET	\$124,639,824.00	m. Federal Share	\$124,639,824.00	n. Non-Federal Share	\$0.00
a. Salaries and Wages	\$4,581,292.00																												
b. Fringe Benefits	\$2,189,594.00																												
c. Total Personnel Costs	\$6,770,886.00																												
d. Equipment	\$994,353.00																												
e. Supplies	\$15,266,233.00																												
f. Travel	\$70,369.00																												
g. Construction	\$0.00																												
h. Other	\$44,266,593.00																												
i. Contractual	\$49,646,230.00																												
j. TOTAL DIRECT COSTS	\$117,014,664.00																												
k. INDIRECT COSTS	\$7,625,160.00																												
l. TOTAL APPROVED BUDGET	\$124,639,824.00																												
m. Federal Share	\$124,639,824.00																												
n. Non-Federal Share	\$0.00																												
<p>31. Assistance Type Cooperative Agreement</p> <p>32. Type of Award Demonstration</p>																													

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-9390GF6	19NU50CK000522PHL2C4	CK	41.51	\$142,473.00	75-X-0140
1-9390H08	19NU50CK000522AMD2C6	CK	41.51	\$1,646,998.00	75-X-0943



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NU50CK000522-02-08

FAIN# NU50CK000522

Federal Award Date: 05/12/2021

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

New Hampshire DHHS

6 NU50CK000522-02-08

1. Terms and Conditions

ADDITIONAL AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CK19-1904, entitled *Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases(ELC)*, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NOA).

Supplemental Component Funding: Additional funding in the amount \$1,789,471 is approved for the Year 02 budget period, which is August 1, 2020 through July 31, 2021, this award. The availability of funds is shown below.

COVID Funded Component	Amount	End of Funding Availability	Suffix Document Number in PMS
Project E: AMD Sequencing & Analytics	\$1,646,998	July 31, 2024	AMD2C6
Strengthening PHL Preparedness	\$142,473	July 31, 2022	PHL2C4

Coronavirus Disease 2019 (COVID-19) Funds: A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139); the Consolidated Appropriations Act and the Coronavirus Response and Relief Supplement Appropriations Act, 2021 (P.L. 116-260) and/or the American Rescue Plan of 2021 [P.L. 117-2] agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS-CoV-2 or to diagnose a possible case of COVID-19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC. HHS laboratory reporting guidance is posted at: <https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf>.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited

to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, recipient is expected to flow down these terms to any subaward, to the extent applicable to activities set out in such subaward.

To achieve the public health objectives of ensuring the health, safety, and welfare of all Americans, Recipient must distribute or administer vaccine without discriminating on non-public-health grounds within a prioritized group.

Unallowable Costs:

1. Research
2. Clinical care
3. Publicity and propaganda (lobbying):
4. Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - a. publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - b. the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body o See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients:
https://www.cdc.gov/grants/documents/AntiLobbying_Restrictions_for_CDC_Grantees_July_2012.pdf
5. All unallowable costs cited in CDC-RFA-CK19-1904 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 -- Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.

COVID-19 Funding Budget Revision Requirement: The recipient must submit a revised budget with a narrative justification within 90 days of receipt of the Notice of Award. If the date falls on a weekend or holiday, the submission will be due the following business day. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the Awarding Agency Contact Information section on the first page before the due date.

REPORTING REQUIREMENTS

The following is a summary of the reporting requirements for the *AMD Sequencing & Analytics*.

1. Within five (5) business days of receipt of this guidance, the Authorized Official is required to acknowledge receipt of this guidance by submitting a Grant Note in GrantSolutions.
2. Quarterly progress reports on milestones in approved workplans via REDCap.
3. Monthly fiscal reports (beginning 30 days after NOAs are issued).

4. Performance measure data.
5. CDC may require recipients to develop annual progress reports (APRs). CDC will provide APR guidance and optional templates should they be required.

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Cathleen Franklin, Grants Management Specialist
Centers for Disease Control and Prevention
Branch 1
2939 Flowers Road, MS-TV-2 Atlanta, GA 30341
Email: qtm0@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)
AND

U.S. Department of Health and Human Services Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator 3301 Independence Avenue, SW
Cohen Building, Room 5527 Washington, DC 20201
Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or Email:
MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC

20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of **Page 2** of the Notice of Award must be known to draw down funds.

Stewardship: The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.